| Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma | Nature communications |  | | 2026 | 34 | 22 |
|
| Unveiling the molecular architecture of T cells and immune synapses with cryo-expansion microscopy | Cell reports | | | 2026 | 8 | 26 |
|
| MYCT1–IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion | The Journal of experimental medicine | | | 2026 | 11 | 10 |
|
| The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity | Molecular oncology | | | 2026 | 14 | 22 |
|
| CAR-T cell therapies are coming after glioblastoma : An overview of early phase clinical trials and future perspectives | iScience | | | 2026 | 8 | 44 |
|
| Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma | Molecular therapy. Nucleic acids | | | 2025 | 8 | 47 |
|
| Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma | JCI insight | | | 2025 | 8 | 33 |
|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences | | | 2025 | 195 | 159 |
|
| Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma | Journal for immunotherapy of cancer | | | 2025 | 9 | 24 |
|
| Dendritic cell progenitors engineered to express extracellular-vesicle–internalizing receptors enhance cancer immunotherapy in mouse models | Nature communications | | | 2025 | 32 | 207 |
|
| Magnetic bead-sensitized optoporation coupled with antibodies-based activation for mRNA CAR-T cell manufacturing | Molecular therapy. Methods & clinical development | | | 2025 | 68 | 225 |
|
| CAR T cell therapy for meningioma : mesothelin emerges as a novel promising target | Neuro-oncology | | | 2025 | 45 | 3 |
|
| Glioma mimicking a cystic infectious disease : A case report of multifocal, multicentric cystic glioblastoma | Surgical neurology international | | | 2025 | 65 | 66 |
|
| Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence | Nature biomedical engineering | | | 2025 | 35 | 27 |
|
| Surgical and clinical impacts of mixed reality-guided glioblastoma resection versus standard neuronavigation: improving tumor surgery | Frontiers in oncology | | | 2025 | 77 | 157 |
|
| Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure | Nature cancer | | | 2025 | 81 | 214 |
|
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | | 2024 | 312 | 373 |
|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | | 2024 | 119 | 249 |
|
| A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy | Molecular therapy. Oncology | | | 2024 | 223 | 207 |
|
| Corticosteroid therapy in older adults with cancer : Expert recommendations from a task force of the International Society of Geriatric Oncology | Journal of geriatric oncology |  | | 2024 | 46 | 0 |
|
| A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol | BMC cancer | | | 2024 | 160 | 412 |
|
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | | 2024 | 145 | 84 |
|
| Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial | Nature cancer | | | 2024 | 391 | 3 |
|
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance | Cancer research communications | | | 2023 | 157 | 86 |
|
| ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board? | BMJ health & care informatics | | | 2023 | 172 | 112 |
|
| Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma : What happened to the evidence ? | Revue neurologique | | | 2023 | 9 | 29 |
|
| An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy | Praxis | | | 2023 | 128 | 0 |
|
| Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | The New England journal of medicine | | | 2023 | 259 | 1,332 |
|
| Reductive carboxylation epigenetically instructs T cell differentiation | Nature | | | 2023 | 235 | 0 |
|
| PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | | | | 2023 | 252 | 799 |
|
| The potential role of the microbiota in prostate cancer pathogenesis and treatment | Nature reviews. Urology | | | 2023 | 133 | 0 |
|
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | | 2023 | 334 | 281 |
|
| Incidence of cisplatin-induced ototoxicity in adult cancer patients based on audiometric confirmation of patient self-report | Frontiers in audiology and otology | | | 2023 | 139 | 1,210 |
|
| c-Met+ Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models | Biomedicines | | | 2023 | 67 | 312 |
|
| Novel pathophysiological insights into CAR-T cell associated neurotoxicity | Frontiers in neurology | | | 2023 | 178 | 283 |
|
| Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy | Nature cancer | | | 2023 | 344 | 370 |
|
| Cancer vaccines | Cancer cell | | | 2022 | 320 | 267 |
|
| The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function | Cell metabolism | | | 2022 | 810 | 772 |
|
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | | 2022 | 100 | 213 |
|
| Clinical relevance of tumour-associated macrophages | Nature reviews. Clinical oncology | | | 2022 | 573 | 1 |
|
| CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives | Biomedicines | | | 2022 | 233 | 407 |
|
| Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis | Diagnostics | | | 2022 | 104 | 98 |
|
| Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis | Journal of neuro-oncology | | | 2022 | 273 | 1 |
|
| Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies | International Journal of Molecular Sciences | | | 2021 | 268 | 490 |
|
| Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma | Frontiers in Immunology | | | 2021 | 471 | 572 |
|
| Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | | | 2021 | 344 | 170 |
|
| Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells | Human gene therapy | | | 2021 | 222 | 0 |
|
| Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) | Swiss Medical Weekly | | | 2021 | 320 | 299 |
|
| From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review | Cancers (Basel) | | | 2021 | 271 | 497 |
|
| Cellules CAR-T pour le traitement des tumeurs solides : présent et futur | Revue médicale suisse | | | 2021 | 347 | 587 |
|
| Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors | International Journal of Molecular Sciences | | | 2020 | 303 | 507 |
|
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | | 2020 | 494 | 354 |
|
| Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | | | 2020 | 362 | 204 |
|
| Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies | Cell | | | 2020 | 417 | 0 |
|
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | | 2019 | 861 | 917 |
|
| Current strategies for vaccination in glioblastoma | Current Opinion in Oncology | | | 2019 | 410 | 5 |
|
| Actively personalized vaccination trial for newly diagnosed glioblastoma | Nature | | | 2019 | 577 | 12 |
|
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | | | 2019 | 380 | 256 |
|
| CAR T-Cell Therapies in Glioblastoma: A First Look | Clinical Cancer Research | | | 2018 | 605 | 2 |
|
| Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development | ILAR journal | | | 2018 | 226 | 0 |
|
| Glycan-directed CAR-T cells | Glycobiology | | | 2018 | 247 | 0 |
|
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | | 2018 | 676 | 459 |
|
| BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma | Neurology | | | 2017 | 556 | 272 |
|
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | | | 2017 | 667 | 9 |
|
| Rapidly Growing Pulmonary Metastasis from Anaplastic Meningioma with Lethal Outcome: A Case Report | Journal of Neurological Surgery Reports | | | 2017 | 575 | 266 |
|
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | | | 2017 | 436 | 0 |
|
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | | 2016 | 544 | 495 |
|
| Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes | Journal of neuro-oncology | | | 2016 | 537 | 702 |
|
| Progrès dans l'immunothérapie des tumeurs cérébrales : difficultés et perspectives | Revue médicale suisse | | | 2016 | 360 | 2 |
|
| Medulloblastoma in children and adults: one distinct disease entity? | Bulletin suisse du cancer | | | 2016 | 517 | 97 |
|
| Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review | CNS oncology | | | 2015 | 520 | 0 |
|
| Lymphome cérébral : une présentation classique ? | Revue médicale suisse | | | 2015 | 410 | 659 |
|
| Immunotherapy of Brain Tumors | Progress in tumor research | | | 2015 | 598 | 0 |
|
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | | | 2015 | 511 | 262 |
|
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy |  | | 2013 | 558 | 0 |
|
